Live Earnings Conference Call: PTC Therapeutics will host a live Q1 2025 earnings call on May 6, 2025 at 4:30PM ET. Get details.

PTC Therapeutics (PTCT) Financials

$40.65 -9.30 (-18.62%)

Closing price 05/5/2025 04:00 PM Eastern

Extended Trading

$40.25 -0.40 (-0.98%)

As of 07:44 AM Eastern

Compare

Annual Income Statements for PTC Therapeutics

This table shows PTC Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363
Consolidated Net Income / (Loss)	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363
Net Income / (Loss) Continuing Operations	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363
Total Pre-Tax Income	-170	-142	-78	-128	-240	-403	-518	-587	-696	-363
Total Operating Income	-167	-132	-64	-116	-241	-432	-374	-447	-440	-303
Total Gross Profit	37	83	190	252	295	362	506	654	938	749
Total Revenue	37	83	194	265	307	381	539	699	938	807
Operating Revenue	37	83	194	265	307	381	539	699	938	807
Total Cost of Revenue	0.00	0.00	4.58	13	12	19	32	45	0.00	57
Operating Cost of Revenue	0.00	-	4.58	13	12	19	32	45	-	57
Total Operating Expenses	204	215	254	368	536	794	881	1,102	1,377	1,052
Selling, General & Admin Expense	82	97	121	154	203	245	286	326	333	301
Research & Development Expense	122	118	117	172	257	478	541	651	667	534
Amortization Expense	0.00	0.00	15	23	28	37	55	117	223	61
Other Operating Expenses / (Income)	-	0.00	0.00	19	48	34	-0.50	-26	-128	-4.48
Impairment Charge	-	-	-	-	-	0.00	0.00	33	218	160
Total Other Income / (Expense), net	-2.83	-9.48	-13	-12	1.23	29	-144	-140	-257	-61
Interest Expense	-	-	-	-	-	-	0.00	0.00	138	0.00
Interest & Investment Income	-2.37	-8.28	-12	-13	-12	-56	-86	-91	-129	-67
Other Income / (Expense), net	-0.47	-1.21	-1.28	0.13	14	85	-58	-49	10	6.54
Income Tax Expense	0.49	0.57	1.34	-0.03	12	35	5.56	-28	-70	0.18
Basic Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)
Weighted Average Basic Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M
Diluted Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)
Weighted Average Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M
Weighted Average Basic & Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	71.36M	73.82M	76.61M	78.87M

This table shows PTC Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-109	-171	-139	-199	-133	-156	-92	-99	-107	-66
Consolidated Net Income / (Loss)	-109	-171	-139	-199	-133	-156	-92	-99	-107	-66
Net Income / (Loss) Continuing Operations	-109	-171	-139	-199	-133	-156	-92	-99	-107	-66
Total Pre-Tax Income	-127	-190	-135	-237	-167	-157	-85	-86	-98	-95
Total Operating Income	-68	-200	-118	-210	-118	5.82	-45	-40	-55	-162
Total Gross Profit	217	143	206	201	187	343	210	187	197	156
Total Revenue	217	167	220	214	197	307	210	187	197	213
Operating Revenue	217	167	220	214	197	307	210	187	197	213
Total Cost of Revenue	0.00	25	14	13	9.49	-36	0.00	0.00	0.00	57
Total Operating Expenses	285	343	324	411	305	338	256	227	251	318
Selling, General & Admin Expense	80	93	87	88	81	76	73	70	73	85
Research & Development Expense	165	189	195	186	164	121	116	132	161	125
Amortization Expense	31	36	39	47	59	77	52	2.87	3.04	3.31
Other Operating Expenses / (Income)	-5.30	6.30	2.40	-129	1.50	-2.70	-0.10	5.10	0.70	-10
Total Other Income / (Expense), net	-59	11	-17	-28	-48	-163	-39	-46	-43	68
Interest & Investment Income	-21	-25	-27	-29	-28	-44	-41	-43	-42	59
Other Income / (Expense), net	-38	35	9.96	1.48	-20	19	1.59	-2.03	-1.87	8.85
Income Tax Expense	-18	-19	3.97	-39	-34	-1.26	6.88	13	8.66	-29
Basic Earnings per Share	($1.53)	($2.35)	($1.88)	($2.66)	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)
Weighted Average Basic Shares Outstanding	71.65M	71.73M	73.73M	74.73M	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M
Diluted Earnings per Share	($1.53)	($2.35)	($1.88)	($2.66)	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)
Weighted Average Diluted Shares Outstanding	71.65M	71.73M	73.73M	74.73M	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M
Weighted Average Basic & Diluted Shares Outstanding	71.88M	73.82M	74.19M	75.34M	75.46M	76.61M	76.70M	76.92M	77.13M	78.87M

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	8.27	0.30	53	58	126	-79	-19	99	314	185
Net Cash From Operating Activities	-124	-104	-10	-28	-99	-194	-251	-357	-158	-108
Net Cash From Continuing Operating Activities	-124	-104	-10	-28	-99	-194	-251	-357	-158	-108
Net Income / (Loss) Continuing Operations	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363
Consolidated Net Income / (Loss)	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363
Depreciation Expense	2.88	3.29	18	26	32	43	64	129	237	76
Amortization Expense	2.59	2.19	0.97	0.09	-1.23	43	7.15	3.61	-0.33	-11
Non-Cash Adjustments To Reconcile Net Income	36	42	37	41	44	92	225	225	411	151
Changes in Operating Assets and Liabilities, net	4.70	-9.16	13	34	78	66	-24	-155	-179	40
Net Cash From Investing Activities	-21	104	13	-43	-387	-562	219	290	-177	44
Net Cash From Continuing Investing Activities	-21	104	13	-43	-387	-562	219	290	-177	44
Purchase of Property, Plant & Equipment	-2.72	-1.78	-3.10	-7.10	-14	-18	-28	-32	-28	-6.50
Acquisitions	0.00	0.00	-77	-57	-36	-38	-57	-120	-92	-68
Purchase of Investments	-224	-85	-81	-69	-494	-1,440	-543	-76	-212	-667
Sale of Property, Plant & Equipment	-	-	-	-	-	-	-	0.00	0.00	28
Sale and/or Maturity of Investments	206	192	175	90	156	944	848	518	156	598
Other Investing Activities, net	-	-	-	-	0.00	-10	-	0.00	0.00	160
Net Cash From Financing Activities	154	0.97	44	132	613	669	21	168	646	256
Net Cash From Continuing Financing Activities	154	0.97	44	132	613	669	21	168	646	256
Repayment of Debt	-	0.00	-0.43	0.00	-12	-29	0.00	-161	-382	0.00
Issuance of Debt	150	0.00	40	0.00	279	0.00	0.00	300	0.00	0.00
Issuance of Common Equity	0.00	0.00	2.47	121	327	33	5.79	56	5.95	5.20
Other Financing Activities, net	4.06	0.97	2.18	11	18	664	15	-27	1,023	251
Effect of Exchange Rate Changes	-0.64	-1.58	6.20	-3.61	-1.30	7.69	-7.82	-2.77	3.11	-7.33
Cash Interest Paid	0.00	4.51	6.27	7.77	7.69	9.80	9.59	18	36	5.82
Cash Income Taxes Paid	0.11	0.94	1.10	1.58	2.11	26	7.71	4.92	14	18

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-54	175	-62	-9.10	-43	429	-46	104	-129	256
Net Cash From Operating Activities	-38	-166	-29	-14	-15	-100	71	-71	-77	-30
Net Cash From Continuing Operating Activities	-38	-166	-29	-14	-15	-100	71	-71	-77	-30
Net Income / (Loss) Continuing Operations	-109	-171	-139	-199	-133	-156	-92	-99	-107	-66
Consolidated Net Income / (Loss)	-109	-171	-139	-199	-133	-156	-92	-99	-107	-66
Depreciation Expense	34	39	43	51	62	81	55	7.02	6.49	6.76
Amortization Expense	0.63	0.51	0.35	0.56	0.57	-1.81	-3.40	-3.00	-2.65	-2.28
Non-Cash Adjustments To Reconcile Net Income	78	24	25	281	47	58	45	30	15	61
Changes in Operating Assets and Liabilities, net	-42	-59	41	-147	9.00	-81	65	-6.08	11	-30
Net Cash From Investing Activities	136	32	-29	-24	-30	-94	-115	-66	-43	268
Net Cash From Continuing Investing Activities	136	32	-29	-24	-30	-94	-115	-66	-43	268
Purchase of Property, Plant & Equipment	-5.38	-8.62	-10	-6.25	-6.36	-5.57	-9.59	7.38	-0.52	-3.77
Acquisitions	-21	-18	-33	-13	-23	-23	-55	-	-10	-2.73
Purchase of Investments	-23	-12	0.00	-18	-8.22	-186	-113	-196	-217	-141
Sale and/or Maturity of Investments	185	72	15	14	7.83	120	63	94	175	265
Other Investing Activities, net	-	-	-	-	-	-	-	-	-	150
Net Cash From Financing Activities	-140	303	4.09	18	3.36	620	0.54	246	-18	26
Net Cash From Continuing Financing Activities	-140	303	4.09	18	3.36	620	0.54	246	-18	26
Issuance of Common Equity	-	53	-	-	-	2.15	-	-	-	3.23
Other Financing Activities, net	10	-39	4.28	15	3.45	1,000	0.54	245	-18	23
Effect of Exchange Rate Changes	-12	6.02	-7.96	10	-2.33	3.10	-2.03	-5.19	8.54	-8.65
Cash Income Taxes Paid	1.08	0.89	2.22	6.98	4.44	0.52	2.04	4.08	6.66	4.77

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	365	269	392	1,119	1,624	2,208	1,938	1,706	1,896	1,705
Total Current Assets	356	261	249	321	779	1,232	954	694	1,219	1,366
Cash & Equivalents	58	58	112	-	288	209	190	280	594	780
Short-Term Investments	281	173	79	58	399	895	584	131	283	360
Accounts Receivable	11	25	40	68	56	70	110	156	161	159
Inventories, net	-	0.00	11	16	19	19	16	22	31	23
Prepaid Expenses	5.93	4.69	6.67	9.25	18	39	55	106	150	44
Plant, Property, & Equipment, net	8.97	7.43	8.38	13	22	34	53	73	87	61
Total Noncurrent Assets	0.36	0.63	134	786	823	943	931	939	590	279
Goodwill	-	-	0.00	82	82	82	82	82	82	82
Intangible Assets	-	0.00	133	701	711	715	725	706	379	119
Other Noncurrent Operating Assets	0.36	0.63	1.22	2.30	30	145	124	151	128	77
Total Liabilities & Shareholders' Equity	365	269	392	1,119	1,624	2,208	1,938	1,706	1,896	1,705
Total Liabilities	139	150	235	768	1,029	1,726	1,937	2,053	2,714	2,803
Total Current Liabilities	45	50	82	167	236	277	509	406	603	581
Accounts Payable	45	49	76	128	159	242	289	320	392	304
Current Deferred Revenue	0.14	0.00	3.94	3.72	8.24	4.15	0.00	1.35	0.80	5.51
Other Current Liabilities	0.00	0.87	1.67	23	48	31	71	85	210	271
Total Noncurrent Liabilities	94	100	153	602	794	1,449	1,427	1,646	2,111	2,222
Long-Term Debt	92	98	145	141	294	309	282	572	284	285
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	0.00	122	131	137	137	103	56	0.00
Other Noncurrent Operating Liabilities	2.05	0.34	0.24	329	365	1,003	1,008	972	1,771	1,937
Total Equity & Noncontrolling Interests	226	120	156	351	594	482	1.44	-347	-819	-1,098
Total Preferred & Common Equity	226	120	156	351	594	482	1.44	-347	-819	-1,098
Total Common Equity	226	120	156	351	594	482	1.44	-347	-819	-1,098
Common Stock	820	856	967	1,288	1,795	2,172	2,124	2,305	2,466	2,575
Retained Earnings	-593	-735	-814	-939	-1,190	-1,629	-2,098	-2,657	-3,284	-3,647
Accumulated Other Comprehensive Income / (Loss)	-1.20	-1.49	3.97	1.46	-11	-61	-24	4.80	-1.29	-26

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,576	1,609	1,338	1,260	1,790	1,916	1,842
Total Current Assets	517	613	590	540	1,169	1,358	1,282
Cash & Equivalents	104	167	208	165	548	655	526
Short-Term Investments	184	119	130	130	336	439	487
Accounts Receivable	124	202	178	166	198	187	200
Inventories, net	15	27	32	36	30	32	36
Prepaid Expenses	90	99	42	44	56	46	33
Plant, Property, & Equipment, net	67	79	82	85	93	66	63
Total Noncurrent Assets	992	916	666	634	528	492	498
Goodwill	82	82	82	82	82	82	82
Intangible Assets	750	686	452	423	330	330	330
Other Noncurrent Operating Assets	160	147	132	129	116	80	85
Total Liabilities & Shareholders' Equity	1,576	1,609	1,338	1,260	1,790	1,916	1,842
Total Liabilities	1,803	2,066	1,917	1,931	2,684	2,897	2,897
Total Current Liabilities	420	442	476	492	575	610	611
Accounts Payable	329	332	359	371	331	339	336
Current Deferred Revenue	-	0.21	0.00	1.22	0.00	0.00	0.00
Other Current Liabilities	91	109	118	120	244	271	274
Total Noncurrent Liabilities	1,383	1,625	1,441	1,439	2,109	2,287	2,286
Long-Term Debt	283	572	573	573	285	285	285
Noncurrent Deferred & Payable Income Tax Liabilities	137	103	52	52	56	56	56
Other Noncurrent Operating Liabilities	963	950	816	813	1,769	1,946	1,945
Total Equity & Noncontrolling Interests	-227	-458	-579	-671	-894	-980	-1,054
Total Preferred & Common Equity	-227	-458	-579	-671	-894	-980	-1,054
Total Common Equity	-227	-458	-579	-671	-894	-980	-1,054
Common Stock	2,223	2,340	2,417	2,447	2,487	2,511	2,531
Retained Earnings	-2,486	-2,796	-2,995	-3,128	-3,375	-3,474	-3,581
Accumulated Other Comprehensive Income / (Loss)	36	-1.59	-1.43	9.61	-5.56	-16	-4.34

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	45.64%	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.20%	-13.97%
EBITDA Growth	-69.27%	21.18%	63.28%	-90.49%	-119.83%	-32.47%	-38.71%	-0.87%	46.97%	-19.98%
EBIT Growth	-68.22%	20.48%	50.80%	-76.23%	-96.82%	-52.39%	-24.74%	-14.87%	13.54%	31.06%
NOPAT Growth	-68.12%	20.98%	51.32%	-79.94%	-108.46%	-79.04%	13.28%	-19.49%	1.77%	31.16%
Net Income Growth	-81.80%	16.63%	44.41%	-62.13%	-96.42%	-74.17%	-19.57%	-6.70%	-12.09%	42.02%
EPS Growth	-70.71%	17.75%	51.56%	-36.14%	-55.27%	-55.50%	-11.90%	-4.85%	-7.45%	43.49%
Operating Cash Flow Growth	-117.09%	16.71%	90.28%	-174.68%	-256.86%	-96.75%	-29.51%	-41.91%	55.58%	32.02%
Free Cash Flow Firm Growth	-92.00%	11.57%	-69.63%	-46.11%	53.73%	302.93%	-200.96%	-99.73%	296.18%	-64.08%
Invested Capital Growth	-25.65%	34.20%	894.42%	150.68%	-19.75%	-241.01%	-8.95%	45.35%	-658.36%	-38.36%
Revenue Q/Q Growth	0.21%	17.73%	37.33%	-14.61%	26.19%	58.68%	-11.80%	0.31%	17.50%	-10.42%
EBITDA Q/Q Growth	-10.44%	15.25%	42.58%	-102.86%	-10.65%	41.09%	-164.54%	-9.06%	54.31%	-1,201.73%
EBIT Q/Q Growth	-10.87%	15.18%	31.28%	-66.22%	-10.21%	33.80%	-115.24%	-10.97%	30.67%	-151.50%
NOPAT Q/Q Growth	-10.57%	14.95%	32.14%	-63.68%	-15.98%	23.03%	-60.50%	-34.84%	31.93%	-125.19%
Net Income Q/Q Growth	-16.13%	14.53%	26.21%	-52.36%	-16.12%	26.27%	-73.36%	-5.20%	2.35%	19.84%
EPS Q/Q Growth	-21.88%	14.90%	30.10%	-67.68%	-3.64%	2.21%	-15.73%	-4.28%	3.24%	20.50%
Operating Cash Flow Q/Q Growth	-21.90%	14.11%	77.47%	-414.46%	4.77%	-38.71%	-1.81%	-37.42%	29.31%	39.49%
Free Cash Flow Firm Q/Q Growth	-7.60%	6.22%	14.45%	-13.59%	9.34%	14.51%	-47.86%	-40.97%	414.05%	-74.58%
Invested Capital Q/Q Growth	-129.79%	-19.52%	-7.94%	-3.98%	-17.34%	4.45%	-2.54%	20.00%	-259.56%	-9.52%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	97.65%	95.21%	96.05%	95.03%	94.00%	93.61%	100.00%	92.89%
EBITDA Margin	-440.98%	-154.51%	-24.14%	-33.76%	-64.01%	-68.36%	-67.03%	-52.11%	-20.59%	-28.72%
Operating Margin	-454.58%	-159.67%	-33.07%	-43.70%	-78.56%	-113.39%	-69.52%	-64.03%	-46.86%	-37.50%
EBIT Margin	-455.84%	-161.13%	-33.73%	-43.65%	-74.09%	-91.02%	-80.27%	-71.07%	-45.78%	-36.69%
Profit (Net Income) Margin	-463.60%	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80.00%	-66.81%	-45.03%
Tax Burden Percent	100.29%	100.40%	101.72%	99.98%	104.86%	108.74%	101.07%	95.15%	90.02%	100.05%
Interest Burden Percent	101.41%	106.21%	118.44%	110.86%	105.49%	116.26%	119.90%	118.30%	162.12%	122.66%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-93.47%	-41.92%	-67.83%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-55.64%	36.03%	-30.82%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	36.23%	-8.58%	14.58%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-65.00%	-82.24%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	323.46%	107.51%	37.91%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-153.44%	-127.86%	-45.92%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-47.99%	-42.00%	-19.84%	-15.30%	-16.58%	-18.09%	-20.85%	-27.26%	-23.85%	-16.44%
Return on Assets (ROA)	-48.80%	-44.79%	-23.90%	-16.95%	-18.34%	-22.87%	-25.27%	-30.68%	-34.80%	-20.18%
Return on Common Equity (ROCE)	-65.00%	-82.24%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	323.46%	107.51%	37.91%
Return on Equity Simple (ROE_SIMPLE)	-75.42%	-118.84%	-50.50%	-36.52%	-42.33%	-90.91%	0.00%	161.06%	76.55%	33.08%
Net Operating Profit after Tax (NOPAT)	-117	-92	-45	-81	-169	-302	-262	-313	-308	-212
NOPAT Margin	-318.20%	-111.77%	-23.15%	-30.59%	-54.99%	-79.38%	-48.67%	-44.82%	-32.80%	-26.25%
Net Nonoperating Expense Percent (NNEP)	-19.01%	-26.11%	-37.83%	-77.95%	-37.01%	-23.29%	-46.07%	-271.75%	-147.83%	-20.94%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-139.42%	57.58%	26.06%
Cost of Revenue to Revenue	0.00%	0.00%	2.35%	4.79%	3.95%	4.97%	6.00%	6.39%	0.00%	7.11%
SG&A Expenses to Revenue	223.25%	117.44%	62.38%	58.00%	65.98%	64.39%	53.06%	46.65%	35.46%	37.30%
R&D to Revenue	331.33%	142.23%	60.42%	64.96%	83.87%	125.44%	100.39%	93.23%	71.08%	66.25%
Operating Expenses to Revenue	554.58%	259.67%	130.72%	138.91%	174.61%	208.42%	163.52%	157.63%	146.86%	130.39%
Earnings before Interest and Taxes (EBIT)	-168	-133	-66	-116	-227	-347	-432	-497	-429	-296
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-162	-128	-47	-89	-196	-260	-361	-364	-193	-232
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.91	3.13	4.42	4.94	4.98	8.64	1,958.20	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	4.91	3.13	29.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	30.20	4.53	3.56	6.54	9.64	10.94	5.23	3.93	2.22	4.32
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	5.86	6.00	11.67	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.48	2.91	3.32	6.26	8.43	8.85	4.59	4.16	1.59	3.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	14.53	0.00	0.00	1.62	7.97
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.41	0.82	0.93	0.44	0.53	0.64	300.02	-1.65	-0.35	-0.26
Long-Term Debt to Equity	0.41	0.82	0.93	0.40	0.49	0.64	196.03	-1.65	-0.35	-0.26
Financial Leverage	-1.07	-1.10	-0.65	-0.24	-0.47	-1.08	-2.35	0.52	0.37	0.75
Leverage Ratio	1.33	1.84	2.39	2.98	2.90	3.56	8.58	-10.54	-3.09	-1.88
Compound Leverage Factor	1.35	1.95	2.84	3.30	3.06	4.14	10.28	-12.47	-5.01	-2.30
Debt to Total Capital	28.90%	45.09%	48.10%	30.38%	34.56%	39.08%	99.67%	254.51%	-53.19%	-35.12%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	2.32%	2.20%	0.00%	34.55%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	28.90%	45.09%	48.10%	28.06%	32.36%	39.08%	65.12%	254.51%	-53.19%	-35.12%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	71.10%	54.91%	51.90%	69.62%	65.44%	60.92%	0.33%	-154.51%	153.19%	135.12%
Debt to EBITDA	-0.57	-0.77	-3.09	-1.71	-1.60	-1.19	-1.20	-1.57	-1.47	-1.23
Net Debt to EBITDA	1.52	1.04	0.99	0.83	1.90	3.05	0.95	-0.44	3.07	3.69
Long-Term Debt to EBITDA	-0.57	-0.77	-3.09	-1.58	-1.50	-1.19	-0.78	-1.57	-1.47	-1.23
Debt to NOPAT	-0.79	-1.06	-3.22	-1.89	-1.86	-1.02	-1.65	-1.83	-0.92	-1.35
Net Debt to NOPAT	2.11	1.44	1.03	0.92	2.21	2.63	1.30	-0.51	1.93	4.03
Long-Term Debt to NOPAT	-0.79	-1.06	-3.22	-1.75	-1.74	-1.02	-1.08	-1.83	-0.92	-1.35
Altman Z-Score	2.12	-2.70	-0.69	0.24	0.83	0.59	-0.83	-1.73	-1.83	-1.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.84	5.27	3.04	1.92	3.30	4.44	1.87	1.71	2.02	2.35
Quick Ratio	7.71	5.17	2.82	0.76	3.15	4.23	1.74	1.39	1.72	2.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-113	-100	-169	-247	-114	232	-234	-468	917	329
Operating Cash Flow to CapEx	-4,571.21%	-5,831.42%	-324.51%	-389.47%	-717.01%	-1,087.66%	-890.84%	-1,113.99%	-557.06%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.67	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.15	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.36	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.11	0.26	0.59	0.35	0.22	0.20	0.26	0.38	0.52	0.45
Accounts Receivable Turnover	4.73	4.59	5.95	4.89	4.97	6.07	5.97	5.25	5.93	5.05
Inventory Turnover	0.00	0.00	0.00	0.94	0.69	1.00	1.87	2.37	0.00	2.13
Fixed Asset Turnover	4.06	10.08	24.60	25.13	17.93	13.75	12.47	11.17	11.75	10.90
Accounts Payable Turnover	0.00	0.00	0.07	0.12	0.08	0.09	0.12	0.15	0.00	0.16
Days Sales Outstanding (DSO)	77.13	79.49	61.33	74.66	73.39	60.14	61.12	69.49	61.58	72.25
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	387.05	532.42	365.94	195.06	153.85	0.00	170.97
Days Payable Outstanding (DPO)	0.00	0.00	4,992.33	2,947.73	4,323.38	3,867.78	2,997.36	2,488.25	0.00	2,213.84
Cash Conversion Cycle (CCC)	77.13	79.49	-4,931.01	-2,486.02	-3,717.57	-3,441.70	-2,741.18	-2,264.91	61.58	-1,970.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-21	-14	110	276	222	-313	-341	-186	-1,411	-1,952
Invested Capital Turnover	-1.94	-4.73	4.04	1.37	1.23	-8.38	-1.65	-2.65	-1.17	-0.48
Increase / (Decrease) in Invested Capital	-4.30	7.21	124	166	-55	-534	-28	154	-1,225	-541
Enterprise Value (EV)	863	241	646	1,657	2,587	3,370	2,474	2,905	1,487	2,627
Market Capitalization	1,110	374	692	1,732	2,960	4,164	2,816	2,744	2,080	3,481
Book Value per Share	$6.59	$3.48	$3.77	$6.95	$9.64	$7.06	$0.02	($4.83)	($10.85)	($14.24)
Tangible Book Value per Share	$6.59	$3.48	$0.57	($8.57)	($3.22)	($4.63)	($11.40)	($15.79)	($16.97)	($16.85)
Total Capital	318	218	301	504	908	791	433	225	-534	-813
Total Debt	92	98	145	153	314	309	431	572	284	285
Total Long-Term Debt	92	98	145	141	294	309	282	572	284	285
Net Debt	-247	-133	-46	-75	-373	-795	-342	161	-593	-854
Capital Expenditures (CapEx)	2.72	1.78	3.10	7.10	14	18	28	32	28	-22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-28	-20	-24	-62	-123	-149	-179	-123	-261	-355
Debt-free Net Working Capital (DFNWC)	311	212	167	166	563	954	595	288	616	785
Net Working Capital (NWC)	311	212	167	154	543	954	445	288	616	785
Net Nonoperating Expense (NNE)	53	50	34	47	83	136	262	246	319	151
Net Nonoperating Obligations (NNO)	-247	-133	-46	-75	-373	-795	-342	161	-593	-854
Total Depreciation and Amortization (D&A)	5.46	5.48	19	26	31	86	71	132	236	64
Debt-free, Cash-free Net Working Capital to Revenue	-77.14%	-24.19%	-12.47%	-23.37%	-40.11%	-39.19%	-33.20%	-17.62%	-27.85%	-44.02%
Debt-free Net Working Capital to Revenue	844.70%	255.92%	85.92%	62.60%	183.54%	250.66%	110.39%	41.15%	65.63%	97.24%
Net Working Capital to Revenue	844.70%	255.92%	85.92%	58.19%	177.02%	250.66%	82.63%	41.15%	65.63%	97.24%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)
Adjusted Weighted Average Basic Shares Outstanding	34.27M	34.56M	41.80M	58.40M	62.63M	70.32M	70.47M	71.73M	74.84M	76.85M
Adjusted Diluted Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)
Adjusted Weighted Average Diluted Shares Outstanding	34.27M	34.56M	41.80M	58.40M	62.63M	70.32M	70.47M	71.73M	74.84M	76.85M
Adjusted Basic & Diluted Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	71.36M	73.82M	76.61M	78.87M
Normalized Net Operating Profit after Tax (NOPAT)	-117	-92	-45	-81	-169	-302	-262	-290	-155	-100
Normalized NOPAT Margin	-318.20%	-111.77%	-23.15%	-30.59%	-54.99%	-79.38%	-48.67%	-41.47%	-16.55%	-12.34%
Pre Tax Income Margin	-462.28%	-171.14%	-39.95%	-48.39%	-78.16%	-105.82%	-96.24%	-84.07%	-74.23%	-45.01%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.12	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.24	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.33	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.44	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	56.50%	1.32%	48.17%	29.17%	-9.47%	83.41%	-4.66%	-12.68%	0.11%	-30.58%
EBITDA Growth	23.61%	-31.65%	8.81%	-62.32%	-6.44%	182.40%	112.61%	75.57%	30.68%	-243.77%
EBIT Growth	4.94%	-42.28%	-9.44%	-64.19%	-30.19%	115.00%	59.26%	79.70%	59.27%	-719.58%
NOPAT Growth	26.74%	-136.45%	-35.94%	-126.87%	-73.29%	102.91%	61.35%	80.81%	53.87%	-2,890.19%
Net Income Growth	18.19%	-19.28%	-9.65%	-30.77%	-21.64%	8.83%	34.10%	50.13%	19.79%	57.71%
EPS Growth	19.05%	-15.76%	-5.62%	-24.88%	-15.03%	11.91%	36.17%	51.50%	21.02%	58.94%
Operating Cash Flow Growth	25.68%	-141.09%	69.72%	74.44%	61.84%	39.57%	339.94%	-406.04%	-430.28%	70.08%
Free Cash Flow Firm Growth	-144.55%	-840.63%	-96.59%	55.51%	152.41%	517.10%	921.87%	2,562.21%	1,652.56%	-65.21%
Invested Capital Growth	29.96%	45.35%	30.31%	-34.92%	-68.73%	-658.36%	-769.88%	-419.10%	-354.23%	-38.36%
Revenue Q/Q Growth	31.17%	-22.90%	31.64%	-2.98%	-8.06%	56.20%	-31.57%	-11.14%	5.40%	8.33%
EBITDA Q/Q Growth	26.13%	-76.67%	48.75%	-142.71%	51.56%	236.77%	-92.16%	-570.07%	-37.47%	-183.63%
EBIT Q/Q Growth	16.09%	-55.36%	34.83%	-93.26%	33.47%	117.90%	-277.00%	3.69%	-33.47%	-172.32%
NOPAT Q/Q Growth	26.17%	-193.81%	41.29%	-78.16%	43.61%	104.93%	-880.98%	11.52%	-35.54%	-197.91%
Net Income Q/Q Growth	28.12%	-56.33%	18.68%	-43.12%	33.14%	-17.16%	41.22%	-8.30%	-7.54%	38.22%
EPS Q/Q Growth	28.17%	-53.59%	20.00%	-41.49%	33.83%	-17.61%	42.03%	-7.50%	-7.75%	38.85%
Operating Cash Flow Q/Q Growth	31.13%	-336.23%	82.23%	52.12%	-2.83%	-590.74%	170.56%	-200.98%	-7.75%	61.03%
Free Cash Flow Firm Q/Q Growth	-13.87%	-100.19%	46.71%	63.38%	234.15%	1,493.23%	5.01%	9.71%	-4.52%	-68.37%
Invested Capital Q/Q Growth	8.93%	20.00%	7.68%	-100.60%	-13.90%	-259.56%	-5.89%	-19.71%	0.34%	-9.52%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	85.12%	93.58%	94.05%	95.17%	111.84%	100.00%	100.00%	100.00%	73.07%
EBITDA Margin	-32.80%	-75.16%	-29.26%	-73.20%	-38.56%	33.76%	3.87%	-20.47%	-26.70%	-69.92%
Operating Margin	-31.40%	-119.67%	-53.37%	-98.01%	-60.11%	1.90%	-21.63%	-21.54%	-27.70%	-76.18%
EBIT Margin	-48.97%	-98.67%	-48.85%	-97.31%	-70.42%	8.07%	-20.87%	-22.63%	-28.65%	-72.03%
Profit (Net Income) Margin	-50.35%	-102.08%	-63.05%	-93.02%	-67.64%	-50.74%	-43.58%	-53.12%	-54.20%	-30.91%
Tax Burden Percent	85.93%	90.09%	102.94%	83.75%	79.82%	99.20%	108.12%	115.68%	108.84%	69.57%
Interest Burden Percent	119.64%	114.83%	125.39%	114.14%	120.34%	-633.76%	193.10%	202.95%	173.80%	61.68%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	871.29%	323.46%	208.43%	162.33%	142.96%	107.51%	85.72%	61.50%	52.54%	37.91%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-19.04%	-37.85%	-22.08%	-50.71%	-39.64%	4.20%	-11.40%	-12.52%	-16.64%	-32.28%
Return on Assets (ROA)	-19.57%	-39.15%	-28.51%	-48.47%	-38.07%	-26.43%	-23.79%	-29.40%	-31.47%	-13.85%
Return on Common Equity (ROCE)	871.29%	323.46%	208.43%	162.33%	142.96%	107.51%	85.72%	61.50%	52.54%	37.91%
Return on Equity Simple (ROE_SIMPLE)	234.19%	0.00%	124.85%	106.69%	95.66%	0.00%	64.80%	48.92%	42.98%	0.00%
Net Operating Profit after Tax (NOPAT)	-48	-140	-82	-147	-83	4.07	-32	-28	-38	-114
NOPAT Margin	-21.98%	-83.77%	-37.36%	-68.60%	-42.08%	1.33%	-15.14%	-15.08%	-19.39%	-53.32%
Net Nonoperating Expense Percent (NNEP)	-27.82%	-33.88%	87.19%	64.64%	36.86%	-74.10%	-38.00%	-24.76%	-30.45%	6.61%
Return On Investment Capital (ROIC_SIMPLE)	-	-62.43%	-	-	-	-0.76%	-	-	-	13.99%
Cost of Revenue to Revenue	0.00%	14.88%	6.42%	5.95%	4.83%	-11.84%	0.00%	0.00%	0.00%	26.93%
SG&A Expenses to Revenue	36.90%	55.38%	39.44%	41.37%	41.15%	24.85%	34.87%	37.22%	37.33%	39.73%
R&D to Revenue	76.21%	112.71%	88.54%	86.94%	83.54%	39.52%	55.27%	70.79%	82.02%	58.53%
Operating Expenses to Revenue	131.40%	204.79%	146.95%	192.05%	155.28%	109.95%	121.63%	121.54%	127.70%	149.25%
Earnings before Interest and Taxes (EBIT)	-106	-165	-108	-208	-138	25	-44	-42	-56	-154
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-71	-126	-64	-156	-76	104	8.13	-38	-53	-149
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.16	3.93	4.64	3.69	2.12	2.22	2.40	2.60	3.17	4.32
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.15	4.16	5.01	3.97	2.46	1.59	1.76	1.71	2.36	3.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	101.08	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	1.62	1.53	1.18	1.64	7.97
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.25	-1.65	-1.25	-0.99	-0.85	-0.35	-0.32	-0.29	-0.27	-0.26
Long-Term Debt to Equity	-1.25	-1.65	-1.25	-0.99	-0.85	-0.35	-0.32	-0.29	-0.27	-0.26
Financial Leverage	3.63	0.52	-0.24	-0.21	-0.30	0.37	0.23	0.37	0.26	0.75
Leverage Ratio	-29.38	-10.54	-6.22	-4.13	-3.16	-3.09	-2.51	-2.09	-1.80	-1.88
Compound Leverage Factor	-35.15	-12.11	-7.80	-4.71	-3.80	19.58	-4.86	-4.24	-3.13	-1.16
Debt to Total Capital	506.31%	254.51%	499.51%	-8,643.67%	-587.05%	-53.19%	-46.69%	-40.96%	-37.06%	-35.12%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	506.31%	254.51%	499.51%	-8,643.67%	-587.05%	-53.19%	-46.69%	-40.96%	-37.06%	-35.12%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-406.31%	-154.51%	-399.51%	8,743.67%	687.05%	153.19%	146.69%	140.96%	137.06%	135.12%
Debt to EBITDA	-0.85	-1.57	-1.60	-1.37	-1.36	-1.47	-2.36	-128.12	13.56	-1.23
Net Debt to EBITDA	0.02	-0.44	-0.80	-0.56	-0.66	3.07	4.98	363.69	-34.63	3.69
Long-Term Debt to EBITDA	-0.85	-1.57	-1.60	-1.37	-1.36	-1.47	-2.36	-128.12	13.56	-1.23
Debt to NOPAT	-1.22	-1.83	-1.71	-1.37	-1.27	-0.92	-1.11	-2.05	-3.03	-1.35
Net Debt to NOPAT	0.02	-0.51	-0.85	-0.56	-0.62	1.93	2.33	5.83	7.74	4.03
Long-Term Debt to NOPAT	-1.22	-1.83	-1.71	-1.37	-1.27	-0.92	-1.11	-2.05	-3.03	-1.35
Altman Z-Score	-0.72	-1.09	-1.01	-1.99	-2.63	-1.04	-1.31	-1.19	-1.31	-1.52
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.23	1.71	1.39	1.24	1.10	2.02	2.03	2.23	2.10	2.35
Quick Ratio	0.98	1.39	1.11	1.08	0.94	1.72	1.88	2.10	1.99	2.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-147	-295	-157	-58	77	1,229	1,291	1,416	1,352	428
Operating Cash Flow to CapEx	-706.89%	-1,924.88%	-287.16%	-226.10%	-228.39%	-1,801.80%	738.02%	0.00%	-15,276.19%	-796.50%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	8.94	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.73	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.77	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.38	0.45	0.52	0.56	0.52	0.55	0.55	0.58	0.45
Accounts Receivable Turnover	6.30	5.25	4.49	5.22	5.50	5.93	4.64	4.94	4.93	5.05
Inventory Turnover	2.40	2.37	2.32	2.20	2.42	0.00	1.81	1.21	0.82	2.13
Fixed Asset Turnover	12.30	11.17	11.12	11.14	10.51	11.75	10.77	12.16	12.15	10.90
Accounts Payable Turnover	0.13	0.15	0.17	0.15	0.18	0.00	0.15	0.11	0.08	0.16
Days Sales Outstanding (DSO)	57.92	69.49	81.28	69.87	66.35	61.58	78.61	73.91	74.10	72.25
Days Inventory Outstanding (DIO)	152.30	153.85	157.17	165.73	150.61	0.00	201.57	301.77	447.65	170.97
Days Payable Outstanding (DPO)	2,911.53	2,488.25	2,168.89	2,430.14	2,085.12	0.00	2,356.75	3,296.17	4,431.68	2,213.84
Cash Conversion Cycle (CCC)	-2,701.31	-2,264.91	-1,930.43	-2,194.54	-1,868.17	61.58	-2,076.57	-2,920.50	-3,909.93	-1,970.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-233	-186	-172	-345	-392	-1,411	-1,494	-1,789	-1,783	-1,952
Invested Capital Turnover	-2.47	-2.65	-3.68	-2.73	-2.55	-1.17	-1.11	-0.84	-0.83	-0.48
Increase / (Decrease) in Invested Capital	99	154	75	-89	-160	-1,225	-1,322	-1,444	-1,390	-541
Enterprise Value (EV)	3,586	2,905	3,861	3,252	1,967	1,487	1,628	1,537	2,126	2,627
Market Capitalization	3,591	2,744	3,576	3,017	1,688	2,080	2,229	2,345	2,854	3,481
Book Value per Share	($3.17)	($4.83)	($6.21)	($7.81)	($8.90)	($10.85)	($11.67)	($12.78)	($13.71)	($14.24)
Tangible Book Value per Share	($14.80)	($15.79)	($16.63)	($15.01)	($15.61)	($16.97)	($17.05)	($18.15)	($19.07)	($16.85)
Total Capital	56	225	115	-6.63	-98	-534	-609	-695	-769	-813
Total Debt	283	572	572	573	573	284	285	285	285	285
Total Long-Term Debt	283	572	572	573	573	284	285	285	285	285
Net Debt	-5.68	161	286	235	278	-593	-600	-808	-728	-854
Capital Expenditures (CapEx)	5.38	8.62	10	6.25	6.36	5.57	9.59	-7.38	0.50	3.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-191	-123	-115	-225	-247	-261	-291	-345	-343	-355
Debt-free Net Working Capital (DFNWC)	97	288	172	113	48	616	594	748	671	785
Net Working Capital (NWC)	97	288	172	113	48	616	594	748	671	785
Net Nonoperating Expense (NNE)	62	31	57	52	50	160	60	71	68	-48
Net Nonoperating Obligations (NNO)	-5.68	161	286	235	278	-593	-600	-808	-728	-854
Total Depreciation and Amortization (D&A)	35	39	43	52	63	79	52	4.02	3.83	4.49
Debt-free, Cash-free Net Working Capital to Revenue	-27.45%	-17.62%	-14.87%	-27.43%	-30.89%	-27.85%	-31.33%	-38.33%	-38.03%	-44.02%
Debt-free Net Working Capital to Revenue	13.95%	41.15%	22.29%	13.84%	6.04%	65.63%	64.06%	83.08%	74.48%	97.24%
Net Working Capital to Revenue	13.95%	41.15%	22.29%	13.84%	6.04%	65.63%	64.06%	83.08%	74.48%	97.24%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.53)	($2.35)	($1.88)	($2.66)	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)
Adjusted Weighted Average Basic Shares Outstanding	71.65M	71.73M	73.73M	74.73M	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M
Adjusted Diluted Earnings per Share	($1.53)	($2.35)	($1.88)	($2.66)	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)
Adjusted Weighted Average Diluted Shares Outstanding	71.65M	71.73M	73.73M	74.73M	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	71.88M	73.82M	74.19M	75.34M	75.46M	76.61M	76.70M	76.92M	77.13M	78.87M
Normalized Net Operating Profit after Tax (NOPAT)	-48	-140	-82	5.78	-83	4.07	-32	-27	-37	-114
Normalized NOPAT Margin	-21.98%	-83.77%	-37.36%	2.70%	-42.08%	1.33%	-15.14%	-14.42%	-18.73%	-53.32%
Pre Tax Income Margin	-58.59%	-113.31%	-61.25%	-111.07%	-84.75%	-51.15%	-40.31%	-45.92%	-49.80%	-44.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.14	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About PTC Therapeutics' Financials

When does PTC Therapeutics's fiscal year end?

According to the most recent income statement we have on file, PTC Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has PTC Therapeutics' net income changed over the last 9 years?

PTC Therapeutics' net income appears to be on an upward trend, with a most recent value of -$363.30 million in 2024, rising from -$170.45 million in 2015. The previous period was -$626.60 million in 2023. Check out PTC Therapeutics' forecast to explore projected trends and price targets.

What is PTC Therapeutics's operating income?

PTC Therapeutics's total operating income in 2024 was -$302.57 million, based on the following breakdown:

Total Gross Profit: $749.38 million
Total Operating Expenses: $1.05 billion

How has PTC Therapeutics revenue changed over the last 9 years?

Over the last 9 years, PTC Therapeutics' total revenue changed from $36.77 million in 2015 to $806.78 million in 2024, a change of 2,094.4%.

How much debt does PTC Therapeutics have?

PTC Therapeutics' total liabilities were at $2.80 billion at the end of 2024, a 3.3% increase from 2023, and a 1,912.6% increase since 2015.

How much cash does PTC Therapeutics have?

In the past 9 years, PTC Therapeutics' cash and equivalents has ranged from $0.00 in 2018 to $779.71 million in 2024, and is currently $779.71 million as of their latest financial filing in 2024.

How has PTC Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, PTC Therapeutics' book value per share changed from 6.59 in 2015 to -14.24 in 2024, a change of -315.9%.

Related Companies

This page (NASDAQ:PTCT) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Financials

Frequently Asked Questions About PTC Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Financials

Annual Income Statements for PTC Therapeutics

Quarterly Income Statements for PTC Therapeutics

Annual Cash Flow Statements for PTC Therapeutics

Quarterly Cash Flow Statements for PTC Therapeutics

Annual Balance Sheets for PTC Therapeutics

Quarterly Balance Sheets for PTC Therapeutics

Annual Metrics and Ratios for PTC Therapeutics

Quarterly Metrics and Ratios for PTC Therapeutics

Frequently Asked Questions About PTC Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools